1. Home
  2. NKTR vs PLX Comparison

NKTR vs PLX Comparison

Compare NKTR & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NKTR
  • PLX
  • Stock Information
  • Founded
  • NKTR 1990
  • PLX 1993
  • Country
  • NKTR United States
  • PLX United States
  • Employees
  • NKTR N/A
  • PLX N/A
  • Industry
  • NKTR Biotechnology: Pharmaceutical Preparations
  • PLX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NKTR Health Care
  • PLX Health Care
  • Exchange
  • NKTR Nasdaq
  • PLX Nasdaq
  • Market Cap
  • NKTR 108.3M
  • PLX 122.6M
  • IPO Year
  • NKTR 1994
  • PLX 1998
  • Fundamental
  • Price
  • NKTR $24.48
  • PLX $1.55
  • Analyst Decision
  • NKTR Strong Buy
  • PLX Strong Buy
  • Analyst Count
  • NKTR 6
  • PLX 1
  • Target Price
  • NKTR $77.50
  • PLX $15.00
  • AVG Volume (30 Days)
  • NKTR 4.6M
  • PLX 1.2M
  • Earning Date
  • NKTR 08-07-2025
  • PLX 08-13-2025
  • Dividend Yield
  • NKTR N/A
  • PLX N/A
  • EPS Growth
  • NKTR N/A
  • PLX N/A
  • EPS
  • NKTR N/A
  • PLX 0.05
  • Revenue
  • NKTR $87,248,000.00
  • PLX $59,764,000.00
  • Revenue This Year
  • NKTR N/A
  • PLX $65.02
  • Revenue Next Year
  • NKTR N/A
  • PLX $57.34
  • P/E Ratio
  • NKTR N/A
  • PLX $31.98
  • Revenue Growth
  • NKTR N/A
  • PLX 0.18
  • 52 Week Low
  • NKTR $6.48
  • PLX $0.82
  • 52 Week High
  • NKTR $37.38
  • PLX $3.10
  • Technical
  • Relative Strength Index (RSI)
  • NKTR 68.00
  • PLX 47.41
  • Support Level
  • NKTR $8.27
  • PLX $1.32
  • Resistance Level
  • NKTR $26.59
  • PLX $1.67
  • Average True Range (ATR)
  • NKTR 3.71
  • PLX 0.11
  • MACD
  • NKTR 1.18
  • PLX 0.04
  • Stochastic Oscillator
  • NKTR 57.06
  • PLX 62.86

About NKTR Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Share on Social Networks: